Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Stock Has Consensus Price Target of $48.71

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has been given a consensus rating of “Hold” by the nine brokerages that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $48.71.

COLL has been the subject of a number of research reports. Barclays reduced their price target on shares of Collegium Pharmaceutical from $56.00 to $48.00 and set an “overweight” rating for the company in a report on Wednesday, August 19th. Oppenheimer assumed coverage on shares of Collegium Pharmaceutical in a report on Wednesday, September 23rd. They issued an “outperform” rating and a $50.00 price target on the stock. Wall Street Zen lowered shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Zacks Research cut shares of Collegium Pharmaceutical from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 6th. Finally, Truist Financial initiated coverage on shares of Collegium Pharmaceutical in a report on Wednesday, September 9th. They set a “buy” rating and a $49.00 price objective for the company.

Collegium Pharmaceutical Stock Performance

COLL traded down $0.08 during trading on Tuesday, hitting $21.97. The stock had a trading volume of 62,296 shares, compared to its average volume of 570,640. The firm has a market cap of $715.44 million, a PE ratio of 17.70, a P/E/G ratio of 0.71 and a beta of 0.73. The company has a current ratio of 1.03, a quick ratio of 0.84 and a debt-to-equity ratio of 3.32. Collegium Pharmaceutical has a 12 month low of $21.43 and a 12 month high of $50.79. The company has a 50 day simple moving average of $24.87 and a 200-day simple moving average of $31.12.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.20. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%. The company had revenue of $199.88 million for the quarter, compared to the consensus estimate of $199.62 million. During the same period last year, the business posted $1.68 earnings per share. The firm’s revenue was up 6.3% compared to the same quarter last year. Analysts expect that Collegium Pharmaceutical will post 6.18 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in COLL. Farther Finance Advisors LLC lifted its position in shares of Collegium Pharmaceutical by 23.1% during the 3rd quarter. Farther Finance Advisors LLC now owns 16,406 shares of the specialty pharmaceutical company’s stock worth $358,000 after buying an additional 3,082 shares during the period. WINTON GROUP Ltd bought a new position in shares of Collegium Pharmaceutical during the second quarter valued at $536,000. Squarepoint Ops LLC lifted its holdings in shares of Collegium Pharmaceutical by 124.8% during the second quarter. Squarepoint Ops LLC now owns 47,897 shares of the specialty pharmaceutical company’s stock valued at $1,734,000 after acquiring an additional 26,589 shares during the period. Corient Private Wealth LP boosted its stake in shares of Collegium Pharmaceutical by 60.5% in the 2nd quarter. Corient Private Wealth LP now owns 71,870 shares of the specialty pharmaceutical company’s stock valued at $2,603,000 after purchasing an additional 27,097 shares in the last quarter. Finally, Amundi boosted its stake in shares of Collegium Pharmaceutical by 188.0% in the 2nd quarter. Amundi now owns 23,492 shares of the specialty pharmaceutical company’s stock valued at $850,000 after purchasing an additional 15,336 shares in the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing, acquiring and commercializing medicines for central nervous system disorders. The company’s portfolio is concentrated in pain management and includes products for chronic and acute pain, opioid-induced constipation and related conditions.

Collegium’s marketed products include Xtampza ER, an extended-release oxycodone formulation designed with the company’s DETERx abuse-deterrent technology; Nucynta and Nucynta ER, tapentadol products for acute and chronic pain; Belbuca, a buprenorphine buccal film for chronic pain; and Symproic, a treatment for opioid-induced constipation.